Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1949 1
1965 1
1968 1
1971 1
1972 1
1975 3
1977 1
1978 3
1979 3
1980 5
1981 3
1982 7
1983 9
1984 6
1985 8
1986 4
1987 12
1988 37
1989 31
1990 31
1991 38
1992 47
1993 84
1994 68
1995 75
1996 63
1997 75
1998 110
1999 87
2000 99
2001 143
2002 147
2003 159
2004 163
2005 194
2006 204
2007 239
2008 274
2009 248
2010 313
2011 316
2012 337
2013 446
2014 763
2015 989
2016 1152
2017 1178
2018 1200
2019 1287
2020 1426
2021 1517
2022 1446
2023 1451
2024 546

Text availability

Article attribute

Article type

Publication date

Search Results

14,858 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for margaret cancer
Your search for Margaret Bancerz retrieved no results
Radiotherapy for Cancer: Present and Future.
Allen C, Her S, Jaffray DA. Allen C, et al. Adv Drug Deliv Rev. 2017 Jan 15;109:1-2. doi: 10.1016/j.addr.2017.01.004. Adv Drug Deliv Rev. 2017. PMID: 28189183 No abstract available.
Evolution of the cancer stem cell model.
Kreso A, Dick JE. Kreso A, et al. Cell Stem Cell. 2014 Mar 6;14(3):275-91. doi: 10.1016/j.stem.2014.02.006. Cell Stem Cell. 2014. PMID: 24607403 Free article. Review.
Genetic analyses have shaped much of our understanding of cancer. However, it is becoming increasingly clear that cancer cells display features of normal tissue organization, where cancer stem cells (CSCs) can drive tumor growth. ...We offer an approach to in …
Genetic analyses have shaped much of our understanding of cancer. However, it is becoming increasingly clear that cancer cells …
Spatially confined sub-tumor microenvironments in pancreatic cancer.
Grünwald BT, Devisme A, Andrieux G, Vyas F, Aliar K, McCloskey CW, Macklin A, Jang GH, Denroche R, Romero JM, Bavi P, Bronsert P, Notta F, O'Kane G, Wilson J, Knox J, Tamblyn L, Udaskin M, Radulovich N, Fischer SE, Boerries M, Gallinger S, Kislinger T, Khokha R. Grünwald BT, et al. Cell. 2021 Oct 28;184(22):5577-5592.e18. doi: 10.1016/j.cell.2021.09.022. Epub 2021 Oct 12. Cell. 2021. PMID: 34644529 Free article.
Molecular profiling for precision cancer therapies.
Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Malone ER, et al. Genome Med. 2020 Jan 14;12(1):8. doi: 10.1186/s13073-019-0703-1. Genome Med. 2020. PMID: 31937368 Free PMC article. Review.
The number of druggable tumor-specific molecular aberrations has grown substantially in the past decade, with a significant survival benefit obtained from biomarker matching therapies in several cancer types. Molecular pathology has therefore become fundamental not only to …
The number of druggable tumor-specific molecular aberrations has grown substantially in the past decade, with a significant survival benefit …
Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy.
Mikubo M, Inoue Y, Liu G, Tsao MS. Mikubo M, et al. J Thorac Oncol. 2021 Nov;16(11):1798-1809. doi: 10.1016/j.jtho.2021.07.017. Epub 2021 Aug 3. J Thorac Oncol. 2021. PMID: 34352380 Free article. Review.
Thus, cancer persistence is a major obstacle to curing cancers, where insight into the biology of DTP cells and therapeutic strategies targeting this mechanism can have considerable clinical implications. ...Herein, we review and discuss the various proposed mechani …
Thus, cancer persistence is a major obstacle to curing cancers, where insight into the biology of DTP cells and therapeutic st …
MYC protein interactors in gene transcription and cancer.
Lourenco C, Resetca D, Redel C, Lin P, MacDonald AS, Ciaccio R, Kenney TMG, Wei Y, Andrews DW, Sunnerhagen M, Arrowsmith CH, Raught B, Penn LZ. Lourenco C, et al. Nat Rev Cancer. 2021 Sep;21(9):579-591. doi: 10.1038/s41568-021-00367-9. Epub 2021 Jun 29. Nat Rev Cancer. 2021. PMID: 34188192 Review.
The transcription factor and oncoprotein MYC is a potent driver of many human cancers and can regulate numerous biological activities that contribute to tumorigenesis. How a single transcription factor can regulate such a diverse set of biological programmes is central to …
The transcription factor and oncoprotein MYC is a potent driver of many human cancers and can regulate numerous biological activities …
Endogenous Retroelements and the Viral Mimicry Response in Cancer Therapy and Cellular Homeostasis.
Chen R, Ishak CA, De Carvalho DD. Chen R, et al. Cancer Discov. 2021 Nov;11(11):2707-2725. doi: 10.1158/2159-8290.CD-21-0506. Epub 2021 Oct 14. Cancer Discov. 2021. PMID: 34649957 Review.
Features of the cancer epigenome distinguish cancers from their respective cell of origin and establish therapeutic vulnerabilities that can be exploited through pharmacologic inhibition of DNA- or histone-modifying enzymes. ...Further characterization of viral mimi …
Features of the cancer epigenome distinguish cancers from their respective cell of origin and establish therapeutic vulnerabil …
The Proteogenomic Landscape of Curable Prostate Cancer.
Sinha A, Huang V, Livingstone J, Wang J, Fox NS, Kurganovs N, Ignatchenko V, Fritsch K, Donmez N, Heisler LE, Shiah YJ, Yao CQ, Alfaro JA, Volik S, Lapuk A, Fraser M, Kron K, Murison A, Lupien M, Sahinalp C, Collins CC, Tetu B, Masoomian M, Berman DM, van der Kwast T, Bristow RG, Kislinger T, Boutros PC. Sinha A, et al. Cancer Cell. 2019 Mar 18;35(3):414-427.e6. doi: 10.1016/j.ccell.2019.02.005. Cancer Cell. 2019. PMID: 30889379 Free PMC article.
DNA sequencing has identified recurrent mutations that drive the aggressiveness of prostate cancers. Surprisingly, the influence of genomic, epigenomic, and transcriptomic dysregulation on the tumor proteome remains poorly understood. We profiled the genomes, epigenomes, t …
DNA sequencing has identified recurrent mutations that drive the aggressiveness of prostate cancers. Surprisingly, the influence of g …
MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer.
Madariaga A, Lau J, Ghoshal A, Dzierżanowski T, Larkin P, Sobocki J, Dickman A, Furness K, Fazelzad R, Crawford GB, Lheureux S. Madariaga A, et al. Support Care Cancer. 2022 Jun;30(6):4711-4728. doi: 10.1007/s00520-022-06889-8. Epub 2022 Mar 10. Support Care Cancer. 2022. PMID: 35274188 Free PMC article.
PURPOSE: To provide evidence-based recommendations on the management of malignant bowel obstruction (MBO) for patients with advanced cancer. METHODS: The Multinational Association for Supportive Care in Cancer (MASCC) MBO study group conducted a systematic review of …
PURPOSE: To provide evidence-based recommendations on the management of malignant bowel obstruction (MBO) for patients with advanced canc …
Leiomyosarcoma: Current Clinical Management and Future Horizons.
Devaud N, Vornicova O, Abdul Razak AR, Khalili K, Demicco EG, Mitric C, Bernardini MQ, Gladdy RA. Devaud N, et al. Surg Oncol Clin N Am. 2022 Jul;31(3):527-546. doi: 10.1016/j.soc.2022.03.011. Surg Oncol Clin N Am. 2022. PMID: 35715148 Review.
14,858 results
You have reached the last available page of results. Please see the User Guide for more information.